Haploidentical stem cell transplantation: anti-thymocyte globulin-based experience

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Haploidentical stem cell transplantation (haplo-SCT) is a vital treatment for hematological malignancies.
• Traditional haplo-SCT protocols faced challenges like graft rejection and graft-versus-host disease (GVHD).
• Anti-thymocyte globulin (ATG) has emerged as a key component in conditioning regimens.

Purpose of the Study:

• To evaluate the efficacy and safety of haplo-SCT with an ATG preparative regimen.
• To assess outcomes including immune tolerance, hematopoietic recovery, GVHD, and non-relapse mortality (NRM).
• To compare unmanipulated haploidentical blood and marrow transplantation (HBMT) outcomes with other donor sources.

Main Methods:

• Utilizing an ATG-based preparative regimen in haplo-SCT.
• Employing unmanipulated grafts in HBMT.
• Analyzing patient data for survival rates, GVHD incidence, and NRM.

Main Results:

• ATG-based haplo-SCT induces immune tolerance, promotes rapid hematopoietic recovery, and effectively prevents GVHD.
• This protocol is associated with significantly lower NRM.
• Survival rates in HBMT with ATG are comparable to HLA-matched sibling or unrelated donor transplantation.
• Unmanipulated HBMT is a viable post-remission strategy for acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) with unfavorable cytogenetics.

Conclusions:

• ATG-based haplo-SCT is a safe and effective strategy for hematological diseases.
• Unmanipulated HBMT with ATG offers outcomes comparable to other donor types.
• Future research should refine donor selection, optimize grafts, and address graft failure and relapse.